Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
IBRX 
Immunitybio Inc (IBRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/20/2025: IBRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $10.2
1 Year Target Price $10.2
| 3 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -80.39% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/20/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.11B USD | Price to earnings Ratio - | 1Y Target Price 10.2 |
Price to earnings Ratio - | 1Y Target Price 10.2 | ||
Volume (30-day avg) 5 | Beta -0.06 | 52 Weeks Range 1.83 - 5.43 | Updated Date 11/20/2025 |
52 Weeks Range 1.83 - 5.43 | Updated Date 11/20/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.41 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-07 | When - | Estimate -0.1071 | Actual -0.07 |
Profitability
Profit Margin - | Operating Margin (TTM) -173.51% |
Management Effectiveness
Return on Assets (TTM) -36.89% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2352863875 | Price to Sales(TTM) 25.53 |
Enterprise Value 2352863875 | Price to Sales(TTM) 25.53 | ||
Enterprise Value to Revenue 28.5 | Enterprise Value to EBITDA -8.99 | Shares Outstanding 984965179 | Shares Floating 336375458 |
Shares Outstanding 984965179 | Shares Floating 336375458 | ||
Percent Insiders 66.41 | Percent Institutions 14.84 |
Upturn AI SWOT
Immunitybio Inc
Company Overview
History and Background
Immunitybio Inc. was founded with the goal of developing next-generation immunotherapies to treat cancer and infectious diseases. They have focused on developing innovative approaches to activate the body's immune system to fight diseases.
Core Business Areas
- Oncology: Development of therapies targeting various cancers using novel immunotherapy platforms such as cell therapies and cytokine fusion proteins.
- Infectious Diseases: Development of vaccines and immunotherapies for infectious diseases, including HIV.
- Clinical Trials and Research: Conducting clinical trials to evaluate the safety and efficacy of its product candidates and conducting research to discover new immunotherapy targets.
Leadership and Structure
The leadership team consists of experienced executives in the biotechnology and pharmaceutical industries. The company is structured to support research, development, clinical trials, and manufacturing.
Top Products and Market Share
Key Offerings
- Anktiva (N-803): An IL-15 superagonist immunotherapy designed to activate the immune system to fight cancer and viral infections. Currently, the drug is approved in combination with BCG for bladder cancer. ImmunityBio faces competition from established pharmaceutical companies in the oncology space, including Merck with Keytruda and Bristol Myers Squibb with Opdivo. Market share is nascent, pending further approvals and market penetration.
Market Dynamics
Industry Overview
The immunotherapy market is rapidly growing, driven by the increasing incidence of cancer and infectious diseases, and the growing adoption of immunotherapy approaches. Technological advancements and increasing investment in research and development are also fueling market growth.
Positioning
Immunitybio Inc. aims to be a leader in the field of immunotherapy by developing novel and differentiated products. Their competitive advantages include their proprietary immunotherapy platforms and their focus on difficult-to-treat cancers and infectious diseases.
Total Addressable Market (TAM)
The global immunotherapy market is expected to reach hundreds of billions of dollars. Immunitybio is positioned to capture a portion of this market through successful development and commercialization of its product candidates.
Upturn SWOT Analysis
Strengths
- Novel immunotherapy platforms
- Experienced leadership team
- Focus on unmet medical needs
- Strong intellectual property portfolio
Weaknesses
- Limited commercial products
- Dependence on clinical trial success
- High cash burn rate
- Competition from established pharmaceutical companies
Opportunities
- Expanding product pipeline through research and development
- Securing regulatory approvals for its product candidates
- Partnering with other companies to commercialize its products
- Expanding into new therapeutic areas
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other immunotherapy companies
- Patent challenges
Competitors and Market Share
Key Competitors
- MRK
- BMY
- PFE
Competitive Landscape
Immunitybio faces significant competition from established pharmaceutical companies with larger resources and approved immunotherapy products. The company's competitive advantage lies in its novel technology and focus on difficult-to-treat diseases.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is unavailable.
Future Projections: Future growth projections are based on analyst estimates for the success of Anktiva and other pipeline products.
Recent Initiatives: Recent initiatives include securing regulatory approvals for Anktiva, advancing clinical trials for other product candidates, and expanding its manufacturing capabilities.
Summary
Immunitybio is a biotech company focused on innovative immunotherapies with the recent approval of Anktiva being a major milestone. Its future hinges on successful clinical trials and commercialization of its pipeline products. The company faces challenges related to competition, regulatory hurdles, and cash burn. Strategic partnerships and continued innovation will be crucial for long-term success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on individual research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Immunitybio Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2015-07-28 | President, CEO & Director Mr. Richard Gerald Adcock | ||
Sector Healthcare | Industry Biotechnology | Full time employees 673 | Website https://immunitybio.com |
Full time employees 673 | Website https://immunitybio.com | ||
ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeiGene, Ltd. ImmunityBio, Inc. is based in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.